Curanex Pharmaceuticals Inc CURX
Curanex Pharmaceuticals Inc (Nasdaq: CURX) is a GI/hepatology drug developer. Its lead program, Phyto-N, is in Pre-clinical for Ulcerative colitis (lead); also atopic dermatitis, rheumatoid arthritis, gout, diabetic foot, cancer cachexia. Its next catalyst on record is Phyto-N: Pre-IND meeting with FDA (October 2026).
Upcoming catalysts
- October 2026Phyto-N — Pre-IND meeting with FDA
The Company plans to hold a pre-IND meeting with the FDA in October 2026.
Next further out: Phyto-N — IND submission for ulcerative colitis (Q4 2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Phyto-N (botanical extract) | Ulcerative colitis (IND planned Q4 2026) | unclear | Pre-clinical |
| Phyto-N | Cancer cachexia (second core indication) | unclear | Pre-clinical |
| Phyto-N | Atopic dermatitis, rheumatoid arthritis, gouty arthritis, diabetic foot | unclear | Pre-clinical |
Recent results and decisions
- Sep 14, 2026n/a Second putative securities class action filed against Curanex, officers, directors, auditor, and underwriters regarding August 2025 IPO.
The complaint asserts claims under Sections 11 and 12(a)(2) of the Securities Act against all named defendants and Section 15 claims against the named individual defendants.
Filing - Jul 23, 2026n/a Putative securities class action filed against Curanex and underwriters alleging misstatements in August 2025 IPO offering documents.
The complaint asserts claims under Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended, against the Company and other defendants.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical GI/hepatology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.